Omeprazole
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
A widely prescribed proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD), peptic ulcers, erosive esophagitis, and Zollinger-Ellison syndrome. Omeprazole reduces stomach acid production and allows healing of acid-damaged tissue in the GI tract.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
A widely prescribed proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD), peptic ulcers, erosive esophagitis, and Zollinger-Ellison syndrome. NutriStack rates the supporting evidence as strong. Common adult dosing is 20–40 mg once daily for 4–8 weeks; maintenance 20 mg/day (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete magnesium, vitamin b12, calcium. This profile indexes 12 sources.
The bottom line
Evidence rating strong. Most-documented uses: heals erosive esophagitis, relieves gerd symptoms (heartburn, regurgitation), treats and prevents peptic ulcers. 12 sources indexed (2001–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Irreversibly inhibits the hydrogen/potassium ATPase (H+/K+ ATPase) proton pump on the luminal surface of gastric parietal cells. By covalently binding to cysteine residues on the pump, omeprazole blocks the final step of acid secretion, reducing basal and stimulated gastric acid output by up to 95%.1,2
Dosing & protocol.
Take 30–60 minutes before the first meal of the day for optimal acid suppression
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Magnesium
SignificantChronic acid suppression impairs active intestinal magnesium transport, especially via TRPM6/7-mediated uptake.
Vitamin B12
ModerateReduced gastric acid impairs release of food-bound vitamin B12 from proteins, lowering long-term absorption.
Calcium
ModerateLower gastric acidity reduces dissolution and absorption of less-soluble calcium salts, especially calcium carbonate.
Iron
ModerateReduced gastric acidity lowers conversion and solubility of non-heme iron, decreasing long-term absorption.
Full safety detail.
Side effects
- Headache
- Nausea
- Diarrhea
- Abdominal pain
- Flatulence
- Vitamin B12 deficiency with long-term use
- Hypomagnesemia with prolonged use
- Increased risk of C. difficile infection
- Increased risk of bone fractures (hip, wrist, spine) with long-term use
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
3- 1Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysisPMIDZhuang Q, Chen S, Zhou X, Jia X et al. · The American Journal of Gastroenterology · 2024
PPIs including omeprazole remain effective for healing severe esophagitis, though newer potassium-competitive acid blockers (P-CABs) showed faster healing rates in some comparisons
- 2Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta-analysisPMIDChoudhury A, Jena A, Jearth V, Dutta AK et al. · Expert Review of Gastroenterology & Hepatology · 2023
Long-term proton pump inhibitor use was significantly associated with vitamin B12 deficiency, suggesting monitoring of B12 levels in patients on chronic PPI therapy
- 3Efficacy of omeprazole/sodium bicarbonate treatment in gastroesophageal reflux disease: a systematic reviewPMIDHiguera-de-la-Tijera F · Medwave · 2018
Higuera-de-la-Tijera F. Efficacy of omeprazole/sodium bicarbonate treatment in gastroesophageal reflux disease: a systematic review. Medwave. 2018
Randomized controlled trials
1- 4Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trialPMIDRichter JE, Kahrilas PJ, Johanson J et al. · The American journal of gastroenterology · 2001
Richter JE, Kahrilas PJ, Johanson J et al.. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. The American journal of gastroenterology. 2001
Reviews & position papers
3- 5Updating understanding of real-world adverse events associated with omeprazolePMIDZhang J, An J · PloS one · 2025
Zhang J, An J. Updating understanding of real-world adverse events associated with omeprazole. PloS one. 2025
- 6Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients - A reviewPMIDMiedziaszczyk M, Idasiak-Piechocka I · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
Miedziaszczyk M, Idasiak-Piechocka I. Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients - A review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023
- 7Safety assessment of omeprazole use: a reviewPMIDForgerini M, Mieli S, Mastroianni PC · Sao Paulo medical journal = Revista paulista de medicina · 2018
Forgerini M, Mieli S, Mastroianni PC. Safety assessment of omeprazole use: a review. Sao Paulo medical journal = Revista paulista de medicina. 2018
Reference material
5- 8Sachar H et al. Proton pump inhibitors: risks of long-term use. J Fam Pract. 2013.Source linkedPMID
- 9Freedberg DE et al. The risks and benefits of long-term use of proton pump inhibitors. BMJ. 2017.Source linkedPMID
- 10Chey WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017.Source linkedPMID
- 11Qi Q, Wang R, Liu L et al.. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis. International journal of clinical pharmacology and therapeutics. 2015Source linkedPMID
- 12Bhatt DL, Cryer BL, Contant CF et al.. Clopidogrel with or without omeprazole in coronary artery disease. The New England journal of medicine. 2010Source linkedPMID
Common questions.
Quick answers about Omeprazole, drawn from the data on this page.
What is Omeprazole?
A widely prescribed proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD), peptic ulcers, erosive esophagitis, and Zollinger-Ellison syndrome. Omeprazole reduces stomach acid production and allows healing of acid-damaged tissue in the GI tract.
What is Omeprazole used for?
Commonly cited benefits of Omeprazole include: Heals erosive esophagitis; Relieves GERD symptoms (heartburn, regurgitation); Treats and prevents peptic ulcers; Eradicates H. pylori (as part of combination therapy); Reduces risk of NSAID-associated gastric ulcers. NutriStack rates the overall evidence as strong.
What is a typical dose of Omeprazole?
A typical adult dose of Omeprazole is 20–40 mg once daily for 4–8 weeks; maintenance 20 mg/day (as prescribed by your physician). The commonly recommended form is Delayed-release capsule or oral suspension. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Omeprazole?
Reported side effects include headache, nausea, diarrhea, abdominal pain, flatulence, vitamin b12 deficiency with long-term use. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Omeprazole?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Omeprazole in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.